Robotic vs laparoscopic surgery is now the defining procurement question in minimally invasive care.
iData Research values the global laparoscopic device and accessories market at over $12.6 billion in 2025, growing at a 3.2% CAGR, while the global minimally invasive surgery robotic system market sits near $9 billion and is climbing several times faster.
This guide shows where adoption actually stands in 2026, which companies lead each approach, and what the clinical evidence supports.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Key Takeaways
Robotic surgery is not replacing traditional laparoscopy in 2026. Both markets are growing, and iData Research projects the laparoscopic device market to reach nearly $15.8 billion while the robotic system market passes $22 billion by 2031.
Robotic-assisted laparoscopy has become a third procedural category alongside open and conventional laparoscopic surgery.
Robotic cases still consume laparoscopic devices, including access systems, insufflation, energy platforms and closure tools, so robotic growth reshapes device demand rather than erasing it.
Intuitive Surgical holds the dominant robotic installed base, while Medtronic and CMR Surgical compete on cost and footprint. Medtronic, Ethicon, and Karl Storz lead the conventional laparoscopic device market.
Randomized trial evidence favors robotics on conversion rates and recovery, but consistently shows longer operating times.
Table of Contents
➜ Is robotic surgery replacing traditional laparoscopic surgery
➜ How big is the robotic surgery market compared to laparoscopy
➜ Which companies lead robotic vs laparoscopic surgery
➜ What does the evidence say about robotic vs laparoscopic surgery outcomes
➜ Where is robotic-assisted laparoscopy growing fastest
➜ Why traditional laparoscopy is not going away
Is robotic surgery replacing traditional laparoscopic surgery?
No. In 2026, robotic surgery is not replacing traditional laparoscopic surgery, and Intuitive Surgical, Medtronic, CMR Surgical, Ethicon and Karl Storz are all expanding rather than retreating.
According to iData Research, the global laparoscopic device and accessories market was valued at over $12.6 billion in 2025 and is expected to reach nearly $15.8 billion at a 3.2% CAGR.
Over the same period, the global minimally invasive surgery robotic system market was valued at roughly $9 billion in 2025 and is expected to move past $22 billion by 2031.
The clearer way to read robotic vs laparoscopic surgery is as a change in categories rather than a contest with one winner.
Procedures were historically sorted into open or laparoscopic. iData Research now identifies a third category, robotic-assisted laparoscopy, which has absorbed a portion of cases that were previously done with conventional laparoscopic instruments.
Critically, a robotic case does not remove the need for laparoscopic devices. Robotic procedures still rely on core laparoscopic infrastructure such as access devices, insufflation systems, energy platforms, closure tool,s and smoke evacuation solutions.
That is why the two markets grow together. Robotic adoption reshapes where device demand lands instead of eliminating it.
How big is the robotic surgery market compared to laparoscopy?
Conventional laparoscopy is still the larger installed market, but robotics is the faster-moving one.
The laparoscopic device market is about $3.6 billion larger than the robotic system market as of 2025, at $12.6 billion versus roughly $9 billion.
The growth gap is where the story sits. Laparoscopic devices are compounding at 3.2% annually, while iData Research projects robotic capital equipment to grow at approximately 11.8%.
Robotic disposable instruments and service revenue are growing even faster, at roughly 17.2% and 15.8% respectively, which reflects rising procedural utilization on platforms hospitals have already bought.
Within the laparoscopic market itself, closure devices accounted for nearly 36% of total value in 2025, making them the largest single segment. Direct energy devices ranked among the largest as well, and every remaining segment contributed under 10% of total value.
Those two segments matter for the robotic vs laparoscopic surgery question because staplers, clip applicators, rs and energy platforms are used across both conventional and robotic workflows.
Which companies lead robotic vs laparoscopic surgery?
The two markets have different leaders, and only Medtronic sits near the top of both.
In robotics, Intuitive Surgical maintains a dominant installed base through its da Vinci platform. In December 2025, its da Vinci SP system won three new FDA indications covering inguinal hernia repair, gallbladder removal and appendectomy, broadening single-port robotics into high-volume general surgery.
Medtronic is the most visible challenger. The FDA cleared its Hugo robotic-assisted surgery system for urologic procedures in December 2025, and the first US commercial case followed in February 2026 at Cleveland Clinic, a robotic-assisted prostatectomy in which the patient was discharged the next day.
Medtronic then submitted 510(k) filings in June 2026 to extend Hugo into general and gynecologic surgery, which would put it in direct competition with da Vinci SP in hernia and gallbladder work.
CMR Surgical is the third named platform competitor. It gained FDA clearance for a soft-tissue surgical robot platform in December 2025, and iData Research notes that CMR and Medtronic are pressuring Intuitive specifically on cost sensitivity, footprint constraints, and hybrid laparoscopic-robotic workflows.
Virtuoso Surgical received FDA Breakthrough Device Designation in September 2025 for a system aimed at precise endoscopic and bladder lesion procedures, an early signal of where the next entrants are targeting.
In conventional laparoscopy,y the ranking is different. iData Research placed Medtronic first globally in 2025, driven by strength in closure and direct energy devices, with Ethicon a close second on the back of leadership in ultrasonic devices and European surgeon loyalty.
Karl Storz held third, anchored by leadership in hand instruments and insufflation, supported by its visualization portfolio and integrated operating room solutions.
What does the evidence say about robotic vs laparoscopic surgery outcomes?
Randomized trial evidence gives robotics real advantages in recovery and conversion, and gives laparoscopy the edge on operating time.
A 2025 meta-analysis of seven randomized controlled trials covering 1,731 colorectal cancer patients found that robotic surgery shortened time to return of bowel function by about 0.62 days, reduced major complications and cut conversion to open surgery sharply compared with conventional laparoscopy, while operative time ran roughly 22.7 minutes longer. Details are available through PubMed.
A separate 2025 meta-analysis of nine randomized trials covering 2,758 colorectal cancer patients reached a similar conclusion on conversion rates and margin quality, and reported comparable safety, mortality and overall complication rates between the two approaches. That review is indexed on PubMed as well.
The two reviews disagree on lymph node yield, with one favoring laparoscopy slightly and the other favoring robotics, so that specific outcome should be treated as unsettled.
Outside colorectal work, the advantage narrows further. A December 2025 review of randomized trials comparing robotic and laparoscopic transabdominal preperitoneal inguinal hernia repair found no statistically significant difference in either operative time or complication rates across 300 patients, and it is available on PMC.
The practical read for 2026 is that robotic vs laparoscopic surgery outcomes are close enough in many indications that purchasing decisions turn on capital cost, throughput and surgeon preference rather than on clinical superiority alone.
Where is robotic-assisted laparoscopy growing fastest?
Robotic-assisted laparoscopy has moved out of early-adopter academic centers and into mid-sized hospitals and private institutions.
iData Research reports that adoption outside the United States is most advanced in Western Europe, Japan, South Korea and parts of the Middle East, with emerging uptake in China and Latin America.
Capital investment remains a barrier in price-sensitive markets. What has changed is how hospitals frame the purchase, with robotic platforms increasingly treated as long-term strategic infrastructure rather than discretionary technology.
By specialty, urology is the clearest shift. iData Research identifies prostatectomy as the procedure where volumes have moved most significantly toward robotic-assisted approaches.
Two device segments show the knock-on effects. Hand-assisted laparoscopic sleeves have become more niche as robotics and better visualization reduced the need for manual intra-abdominal access.
Articulating hand instruments moved the other way. Their adoption had been declining, but rising robotic system costs and limited robotic access at some hospitals renewed interest in them for high-precision procedures where full robotic investment is not feasible.
Why traditional laparoscopy is not going away
Three forces keep conventional laparoscopy central through the forecast period.
The first is procedural volume. Laparoscopic procedures continue to grow globally across general surgery, gynecology and urology, even as a portion migrates to robotic platforms.
The second is the hybrid operating room. As robotic procedures expand, demand shifts toward environments that still depend heavily on access systems, energy platforms, insufflation technologies and closure devices, which reinforces those categories across both workflows.
The third is cost. Robotic capital equipment and per-procedure disposables carry a premium that many hospitals and ambulatory surgical centers cannot absorb across their full case mix.
Technology is also advancing on the laparoscopic side. Dual-tube smoke evacuation systems are gaining traction in gynecologic, colorectal, and bariatric procedures, and AI-enabled laparoscopic visualization platforms are being introduced for automated image enhancement and tissue recognition.
For a broader view of how robotic platforms fit into minimally invasive care, see our overview of robotic surgery and the rise of minimally invasive procedures.
Frequently asked questions about robotic vs laparoscopic surgery
Is robotic surgery better than laparoscopic surgery?
Randomized evidence shows robotic surgery reduces conversion to open surgery and speeds return of bowel function in colorectal cases, while taking longer in the operating room. In inguinal hernia repair, the randomized data show no significant difference in operative time or complications, so the answer depends on the indication.
What is robotic-assisted laparoscopy?
Robotic-assisted laparoscopy is a minimally invasive approach in which a surgeon operates laparoscopic instruments through a robotic platform. iData Research treats it as a third procedural category alongside open and conventional laparoscopic surgery.
How large is the robotic surgery market in 2026?
iData Research valued the global minimally invasive surgery robotic system market at roughly $9 billion in 2025 and projects it to surpass $22 billion by 2031.
Does robotic surgery reduce demand for laparoscopic devices?
No. Robotic cases still use access devices, insufflation systems, energy platforms, closure tools,s and smoke evacuation solutions, so robotic growth reshapes laparoscopic device demand rather than removing it.
Which company leads the surgical robotics market?
Intuitive Surgical holds the dominant installed base with its da Vinci platform. Medtronic and CMR Surgical are the closest named challengers, both cleared by the FDA in December 2025 for soft-tissue robotic procedures.
Which company leads the laparoscopic device market?
Medtronic led the global laparoscopic device market in 2025, followed closely by Ethicon and then Karl Storz, according to iData Research.
For full segment forecasts, procedure volumes and competitive market shares across both approaches, see the iData Research Global Laparoscopic Device Market report and the Global Minimally Invasive Surgery Robotic System Market report.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
